🎉 M&A multiples are live!
Check it out!

Krystal Biotech Valuation Multiples

Discover revenue and EBITDA valuation multiples for Krystal Biotech and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Krystal Biotech Overview

About Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.


Founded

2015

HQ

United States of America
Employees

275

Website

krystalbio.com

Financials

LTM Revenue $339M

LTM EBITDA $123M

EV

$4.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Krystal Biotech Financials

Krystal Biotech has a last 12-month revenue of $339M and a last 12-month EBITDA of $123M.

In the most recent fiscal year, Krystal Biotech achieved revenue of $291M and an EBITDA of $110M.

Krystal Biotech expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Krystal Biotech valuation multiples based on analyst estimates

Krystal Biotech P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $50.7M $291M XXX XXX XXX
Gross Profit n/a $47.6M XXX XXX XXX
Gross Margin NaN% 16% XXX XXX XXX
EBITDA $17.9M $110M XXX XXX XXX
EBITDA Margin 35% 38% XXX XXX XXX
Net Profit -$140M $10.9M XXX XXX XXX
Net Margin -276% 4% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Krystal Biotech Stock Performance

As of April 15, 2025, Krystal Biotech's stock price is $169.

Krystal Biotech has current market cap of $4.9B, and EV of $4.3B.

See Krystal Biotech trading valuation data

Krystal Biotech Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$4.3B $4.9B XXX XXX XXX XXX $4.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Krystal Biotech Valuation Multiples

As of April 15, 2025, Krystal Biotech has market cap of $4.9B and EV of $4.3B.

Krystal Biotech's trades at 12.7x LTM EV/Revenue multiple, and 35.0x LTM EBITDA.

Analysts estimate Krystal Biotech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Krystal Biotech and 10K+ public comps

Krystal Biotech Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $4.3B XXX XXX XXX
EV/Revenue 14.8x XXX XXX XXX
EV/EBITDA 39.0x XXX XXX XXX
P/E 54.7x XXX XXX XXX
P/E/Growth 0.6x XXX XXX XXX
EV/FCF 36.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Krystal Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Krystal Biotech Valuation Multiples

Krystal Biotech's NTM/LTM revenue growth is 53%

Krystal Biotech's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Krystal Biotech's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Krystal Biotech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Krystal Biotech and other 10K+ public comps

Krystal Biotech Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 473% XXX XXX XXX XXX
EBITDA Margin 38% XXX XXX XXX XXX
EBITDA Growth 514% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 91% XXX XXX XXX XXX
Revenue per Employee $1.1M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 18% XXX XXX XXX XXX
Opex to Revenue 58% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Krystal Biotech Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Krystal Biotech M&A and Investment Activity

Krystal Biotech acquired  XXX companies to date.

Last acquisition by Krystal Biotech was  XXXXXXXX, XXXXX XXXXX XXXXXX . Krystal Biotech acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Krystal Biotech

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Krystal Biotech

When was Krystal Biotech founded? Krystal Biotech was founded in 2015.
Where is Krystal Biotech headquartered? Krystal Biotech is headquartered in United States of America.
How many employees does Krystal Biotech have? As of today, Krystal Biotech has 275 employees.
Who is the CEO of Krystal Biotech? Krystal Biotech's CEO is Mr. Krish S. Krishnan.
Is Krystal Biotech publicy listed? Yes, Krystal Biotech is a public company listed on NAS.
What is the stock symbol of Krystal Biotech? Krystal Biotech trades under KRYS ticker.
When did Krystal Biotech go public? Krystal Biotech went public in 2017.
Who are competitors of Krystal Biotech? Similar companies to Krystal Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Krystal Biotech? Krystal Biotech's current market cap is $4.9B
What is the current revenue of Krystal Biotech? Krystal Biotech's last 12-month revenue is $339M.
What is the current EBITDA of Krystal Biotech? Krystal Biotech's last 12-month EBITDA is $123M.
What is the current EV/Revenue multiple of Krystal Biotech? Current revenue multiple of Krystal Biotech is 12.7x.
What is the current EV/EBITDA multiple of Krystal Biotech? Current EBITDA multiple of Krystal Biotech is 35.0x.
What is the current revenue growth of Krystal Biotech? Krystal Biotech revenue growth between 2023 and 2024 was 473%.
Is Krystal Biotech profitable? Yes, Krystal Biotech is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.